Repurposing Drugs in Oncology: Current Evidence and Future Traits
Abstract
Drug repurposing can be defined as exploring, researching, and clinical usage of an old clinically approved drug with known risk factors, usually economical, that can be used as an antineoplastic drug.Such use may reduce the time for new drugs to be incorporated into the treatment armamentarium.Repurposing of a particular drug saves time and money.Thus, repurposing drugs in oncology is the easiest and most economical way to recruit new drugs in the treatment armamentarium of oncology.Many of the drugs, ranging from anti-hypertensives, statins, and antibiotics, have actions on cell proliferation pathways, cytotoxic T cell activation, and protein synthesis.All this knowledge can be utilized in prescribing appropriate drugs so as to potentiate the antineoplastic action.Just to give an example, if a particular patient is having endometrioid adenocarcinoma of the endometrium and is having co-morbid hypertension, then according to published literature, calcium channel blockers acting on voltage-gated calcium channels, like amlodipine, can be repurposed for this purpose.In prescribing amlodipine, the physician is well aware of the side effects and cost-effectiveness of amlodipine.Besides, amlodipine cannot only control the hypertension but can also potentiate the action of the co-medication for endometrioid adenocarcinoma of the endometrium.Likewise, fenofibrate, a fibric acid derivative used as an antilipidemic drug, can be repurposed as an antiangiogenic agent.Many of the drugs…
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.